Open Access

[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma

  • Authors:
    • Kai Liu
    • Songyang Liu
    • Wei Zhang
    • Bai Ji
    • Yingchao Wang
    • Yahui Liu
  • View Affiliations

  • Published online on: November 1, 2021     https://doi.org/10.3892/ijo.2021.5280
  • Article Number: 100
  • Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

December-2021
Volume 59 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu K, Liu S, Zhang W, Ji B, Wang Y and Liu Y: [Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol 59: 100, 2021.
APA
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., & Liu, Y. (2021). [Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. International Journal of Oncology, 59, 100. https://doi.org/10.3892/ijo.2021.5280
MLA
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., Liu, Y."[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma". International Journal of Oncology 59.6 (2021): 100.
Chicago
Liu, K., Liu, S., Zhang, W., Ji, B., Wang, Y., Liu, Y."[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma". International Journal of Oncology 59, no. 6 (2021): 100. https://doi.org/10.3892/ijo.2021.5280